Loading...
•
Jun 30, 2025
Rxsight Q2 2025 Earnings Report
RxSight's Q2 2025 earnings report detailed a revenue decrease of 4% year-over-year, alongside increased LAL sales and a net loss of $(11.8) million.
Key Takeaways
RxSight reported a 4% decrease in total revenue to $33.6 million in Q2 2025 compared to the previous year, primarily due to a significant 50% decline in Light Delivery Device (LDD) revenue, despite a 13% increase in Light Adjustable Lens (LAL) revenue. The company experienced a net loss of $(11.8) million, or $(0.29) per share, widening from a net loss of $(6.1) million in Q2 2024. Gross profit improved to $25.2 million, or 74.9% of revenue, driven by a favorable shift towards LAL sales.
Total revenue for Q2 2025 was $33.6 million, a 4% decrease from $34.9 million in Q2 2024.
Light Adjustable Lens (LAL) sales increased by 13%, while Light Delivery Device (LDD) sales decreased by 50% compared to the second quarter of 2024.
The company reported a net loss of $(11.8) million, or $(0.29) per basic and diluted share, compared to a net loss of $(6.1) million, or $(0.16) per share, in Q2 2024.
Gross profit increased to $25.2 million (74.9% of revenue) in Q2 2025, up from $24.3 million (69.5% of revenue) in Q2 2024, driven by a favorable product mix.
Forward Guidance
RxSight reaffirmed its 2025 full-year guidance for revenue, gross margin, and operating expenses, anticipating a revenue decrease of 7% to 14% compared to 2024, an increase in gross margin, and an increase in operating expenses.
Positive Outlook
- Reaffirmed 2025 full-year revenue guidance, indicating stability in future expectations.
- Anticipated gross margin in the range of 72% to 74% for 2025, representing an implied increase of 130 to 330 basis points compared to 2024.
- Strategic investments in clinical affairs, marketing, and education are expected to elevate onboarding and strengthen customer support.
- Newly launched Customer Success Organization aims to deepen engagement with existing customers and expand the installed base.
- FDA approval to expand the Light Adjustable Lens dioptric power range to -2.0 to +3.0 diopters, along with new LDD software updates, enhances product capabilities.
Challenges Ahead
- Full-year 2025 revenue guidance of $120.0 million to $130.0 million represents an implied decrease of 14% to 7% compared to 2024.
- Operating expenses are projected to be in the range of $145.0 million to $155.0 million for 2025, representing an implied increase of 7% to 14% compared to 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...